NCT07709910尚未招募3 期
A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 382
- 试验地点
- 1
- 主要终点
- Change from baseline in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain score after 68 weeks of treatment
研究概览
简要总结
The study is being conducted to evaluate the efficacy and safety of Ribupatide Injection in participants with obesity and knee osteoarthritis, and to explore its improvement on knee joint structure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1、Voluntarily sign the informed consent form, agree to comply with the protocol requirements, and be willing and able to complete the study;
- •2、Aged ≥18 years on the date of signing the informed consent form, male or female;
- •3、BMI ≥28.0 kg/m² at screening;
- •4、Self-reported dietary and exercise control for 3 months or more prior to screening, and body weight change (difference between maximum and minimum body weight within 3 months) ≤5.0 kg in the 3 months prior to screening;
- •5、Based on the American College of Rheumatology criteria, the clinical diagnosis is knee osteoarthritis, and the target knee joint X-ray examination shows a K-L grade of 2-3 at screening.
排除标准
- •Existence of endocrine diseases that may significantly affect body weight;
- •Existence of any conditions affecting gastric emptying;
- •Known history of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, or symptomatic/treated gallbladder diseases;
- •Known history or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2);
- •Severe infection, major trauma, or major/medium surgery within 1 month prior to screening;
- •History of severe cardiovascular or cerebrovascular diseases within 6 months prior to screening;
- •History of malignancy in any organ system within 5 years prior to screening;
- •Existence or suspicion of depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illnesses;
- •Known or suspected history of alcohol and/or drug abuse or addiction;
- •Symptoms or signs of acute or chronic hepatitis, or any liver disease other than metabolic dysfunction-associated fatty liver disease;
- •Existence of serious hematologic diseases or any conditions causing hemolysis or red blood cell instability;
- •Existence of autoimmune diseases requiring systemic glucocorticoid or immunosuppressive therapy during the study period;
- •Known or suspected allergy to GLP-1 and/or GIP receptor agonists or their excipients;
- •Participation in any drug or medical device clinical trial within 3 months prior to screening;
- •Blood donation or cumulative blood loss ≥400 mL within 3 months prior to screening, or receipt of blood transfusion within 3 months;
- •Participants with mental incompetence or language impairments that prevent full understanding or participation in the trial process.
结局指标
主要结局
Change from baseline in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain score after 68 weeks of treatment
时间窗: after 68 weeks of continuous treatment, assessed every few weeks
Percentage change from baseline in body weight after 68 weeks of treatment
时间窗: after 68 weeks of continuous treatment, assessed every few weeks
次要结局
- After 68 weeks of treatment, changes from baseline in waist circumference(from first dose to 68 weeks after treatment)
- Adverse events (AE).(from first dose up to week 76)
- After 68 weeks of treatment, changes from baseline in Worst Pain Intensity Numerical Rating Scale (WPI-NRS);(from first dose to 68 weeks after treatment)
- Use of analgesics during the treatment period;(from first dose up to week 72)
- After 68 weeks of treatment, changes from baseline in body weight(from first dose to 68 weeks after treatment)
- After 68 weeks of treatment, changes from baseline in body mass index (BMI)(from first dose to 68 weeks after treatment)
- After 68 weeks of treatment, changes from baseline in WOMAC joint function score;(from first dose to 68 weeks after treatment)
- After 68 weeks of treatment, changes from baseline in WOMAC stiffness score;(from first dose to 68 weeks after treatment)
- After 68 weeks of treatment, changes from baseline in Average Pain Intensity Numerical Rating Scale (API-NRS);(from first dose to 68 weeks after treatment)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Effect of one dose versus two dose injection Rituximab in children with steroid dependent nephrotic syndrome aged between 3-12 years who are difficult to treat with other medications.CTRI/2025/10/096461Renaissa Banik60
进行中（未招募）
3 期
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightObesityNCT07357415Eli Lilly and Company600
招募中
4 期
A Clinical Trial of Tirzepatide (LY3298176) in Subjects With Overweight or Obesity and PCOS-related Ovarian Dysfunction (PERIODS)2024-515982-32-00Rheinische Friedrich-Wilhelms-Universitaet Bonn198
招募中
3 期
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)Chronic Pruritus of Unknown OriginNCT07700056Novartis Pharmaceuticals180
招募中
3 期
Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.NCT07402213Jemincare240